Navigation Links
Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
Date:7/20/2009

CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and six months ended June 30, 2009. At June 30, 2009, Idenix's cash, cash equivalents and marketable securities totaled $51.7 million.

Business Highlights

  • Idenix announced today that it had successfully completed a proof-of-concept study of its lead HCV antiviral development program, IDX184, a novel once-daily liver-targeted nucleotide prodrug. This double-blind, placebo-controlled, monotherapy, dose-escalation study in HCV genotype-1-infected patients evaluated the safety and antiviral activity of IDX184. For more information on the results of this study, please see the related press release issued today by Idenix.
  • The company continued to advance its two preclinical HCV antiviral programs. Idenix is finalizing IND- or CTA-enabling preclinical studies for IDX375, a non-nucleoside polymerase inhibitor, and is preparing documentation to support initial regulatory filings. The company has synthesized the first kilogram of its lead protease inhibitor drug candidate and has initiated 28-day chronic toxicology studies in two species to support regulatory applications.
  • Finally, during the quarter, Idenix streamlined operations with the closure of its screening facility in Cagliari, Italy. This activity is now being performed at the company's laboratory in Cambridge, Massachusetts. As a result, Idenix reduced its workforce by 18 employees and incurred a restructuring charge in the quarter of $1.5 million.

"Our focus this year has been on the advancement of our HCV discov
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
2. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
3. Idenix Pharmaceuticals Reports First Quarter Financial Results
4. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
5. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
6. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
8. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
9. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
10. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
11. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 On Friday, December ... 83, the Omnibus and Continuing Resolution Appropriations Act ... hydrocephalus a condition eligible to receive funding through ... by the Department of Defense (DoD). The Hydrocephalus ... on Capitol Hill, is celebrating this victory for ...
(Date:12/24/2014)... The report expects global cell isolation and expansion market ... a carefully analyzed data about the vital drivers, restraints, ... Full Copy of Report @ http://bit.ly/1yUxy0T , ... expansion will keep witnessing growth at an impressive CAGR ... driven by rapid technological advancements, government funding and investments, ...
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/22/2014)... Brussels (PRWEB) December 22, 2014 The ... the global leader of technical training across the life ... Clinical Data Management (SCDM) to provide the organization's ... certification programs —providing access to the more than 350 ... SCDM members with 10% off when registering for a ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... solutions for biofuels, biochemicals and textile processingPALO ALTO, ... Yesterday, Genencor, a division of Danisco ... Area Research and Development headquarters to a group ... showcased recently announced collaborations for developing sustainable fuels, ...
... 20 Solos Endoscopy, Inc. (Pink Sheets: SNDY) ... signed an agreement with Lifeline Biotechnologies, Inc. (Pink ... product line to Lifeline Biotechnologies for a combination ... Solos Endoscopy originally purchased the products from ...
... 20, Shire plc (LSE: SHP, NASDAQ: SHPGY ... U.S. District Court of the Southern District of,New York ... (collectively "Mylan") for infringement of Shire,s,patent: U.S. Patent No. ... lawsuit was filed in response to an Abbreviated New ...
Cached Biology Technology:Genencor Shows How Industrial Biotech Breakthroughs Contribute to the New Green Economy 2Genencor Shows How Industrial Biotech Breakthroughs Contribute to the New Green Economy 3Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc. 2Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent 2Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent 3
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... products are in the solid dosage form. Particulate ... include crystallization; drying, granulation, and coating; tablet compaction; ... other particulate processes are used for the large-scale ... dry powder inhalants for public consumption. As such, ...
... industries. They focus light to zap tumors and send digital ... But the physical length of an ordinary laser cannot be ... which limits its application in many industries. Now the Spaser, ... can be as small as needed to fuel nano-technologies of ...
... Newly released findings of a multinational survey ... (IOF) show clear disparities between patients, and doctors, ... 13-country survey of 844 postmenopausal patients over 55 ... between patient and doctor understanding of the emotional ...
Cached Biology News:Particulate Processes in the Pharmaceutical Industry III 2Particulate Processes in the Pharmaceutical Industry III 3Particulate Processes in the Pharmaceutical Industry III 4Particulate Processes in the Pharmaceutical Industry III 5Particulate Processes in the Pharmaceutical Industry III 6The 'Spaser' heats up laser technology 2Link between fracture prevention and treatment adherence not fully understood by patients 2
Thermo Forma provides an array of accessory Racks for the Cryo/CryoPlus 16" Diameter storage system. To maximise inventory capacity a Jumbo Arrowhead configuration is recommended. You may choose betw...
... The Forma Incubated Console Orbital ... with class-leading ergonomics, unequalled programming power. ... prevents vibration, allowing the unit to ... A patented HEPA filtration system reduces ...
... shakers combine high durability and capacity with ... heavy-duty mechanism prevents vibration, allowing the unit ... Every other part, from the large rubber ... machined aluminum platform is designed to last ...
The Holten mini vertical flow workbench provides a particle-free environment for sample protection against airborne contaminants....
Biology Products: